EP2723349A4 - Mikro-rna-31-zusammensetzungen und verfahren zu ihrer verwendung bei autoimmunkrankheiten - Google Patents

Mikro-rna-31-zusammensetzungen und verfahren zu ihrer verwendung bei autoimmunkrankheiten

Info

Publication number
EP2723349A4
EP2723349A4 EP12804592.9A EP12804592A EP2723349A4 EP 2723349 A4 EP2723349 A4 EP 2723349A4 EP 12804592 A EP12804592 A EP 12804592A EP 2723349 A4 EP2723349 A4 EP 2723349A4
Authority
EP
European Patent Office
Prior art keywords
microrna
compositions
methods
autoimmune disease
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12804592.9A
Other languages
English (en)
French (fr)
Other versions
EP2723349A2 (de
Inventor
Yihong Yao
Nan Shen
Wei Fan
Yuanjia Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2723349A2 publication Critical patent/EP2723349A2/de
Publication of EP2723349A4 publication Critical patent/EP2723349A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP12804592.9A 2011-06-27 2012-06-26 Mikro-rna-31-zusammensetzungen und verfahren zu ihrer verwendung bei autoimmunkrankheiten Withdrawn EP2723349A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501482P 2011-06-27 2011-06-27
PCT/US2012/044197 WO2013003346A2 (en) 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease

Publications (2)

Publication Number Publication Date
EP2723349A2 EP2723349A2 (de) 2014-04-30
EP2723349A4 true EP2723349A4 (de) 2015-01-14

Family

ID=47424764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12804592.9A Withdrawn EP2723349A4 (de) 2011-06-27 2012-06-26 Mikro-rna-31-zusammensetzungen und verfahren zu ihrer verwendung bei autoimmunkrankheiten

Country Status (8)

Country Link
EP (1) EP2723349A4 (de)
JP (1) JP2014521600A (de)
KR (1) KR20140066671A (de)
AU (1) AU2012275552A1 (de)
BR (1) BR112013033794A2 (de)
CA (1) CA2841158A1 (de)
RU (1) RU2014102217A (de)
WO (1) WO2013003346A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843233A (zh) * 2019-11-26 2021-05-28 中国科学院上海营养与健康研究所 预防皮肤衰老与早衰的内源性小rna分子标靶及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030153A1 (fr) * 2007-08-27 2009-03-12 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Rôles de micro-arn dans le diagnostic et le traitement du lupus érythémateux systémique
WO2010065961A2 (en) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions and methods relating to mir-31

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (de) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030153A1 (fr) * 2007-08-27 2009-03-12 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Rôles de micro-arn dans le diagnostic et le traitement du lupus érythémateux systémique
WO2010065961A2 (en) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions and methods relating to mir-31

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FAN WEI ET AL: "Identification of microRNA-31 as a Novel Regulator Contributing to Impaired IL-2 Production in T cells From Patients With Systemic Lupus Erythematosus", ARTHRITIS & RHEUMATISM, vol. 63, no. 10, Suppl. S, 1922, October 2011 (2011-10-01), & 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETIN; CHICAGO, IL, USA; NOVEMBER 04 -09, 2011, pages S749 - S750, XP002731678 *
GOMEZ-MARTIN D ET AL: "Interleukin 2 and systemic lupus erythematosus", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 1, 1 September 2009 (2009-09-01), pages 34 - 39, XP026574987, ISSN: 1568-9972, [retrieved on 20090306], DOI: 10.1016/J.AUTREV.2009.02.035 *
RUJUAN DAI ET AL: "Identification of a Common Lupus Disease-Associated microRNA Expression Pattern in Three Different Murine Models of Lupus", PLOS ONE, vol. 5, no. 12, 10 December 2010 (2010-12-10), pages e14302, XP055148831, DOI: 10.1371/journal.pone.0014302 *
S. VALASTYAN ET AL: "Concurrent Suppression of Integrin 5, Radixin, and RhoA Phenocopies the Effects of miR-31 on Metastasis", CANCER RESEARCH, vol. 70, no. 12, 15 June 2010 (2010-06-15), pages 5147 - 5154, XP055148658, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-0410 *
WEI FAN ET AL: "Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, vol. 64, no. 11, 27 October 2012 (2012-10-27), pages 3715 - 3725, XP055148804, ISSN: 0004-3591, DOI: 10.1002/art.34596 *

Also Published As

Publication number Publication date
BR112013033794A2 (pt) 2019-09-24
KR20140066671A (ko) 2014-06-02
WO2013003346A2 (en) 2013-01-03
EP2723349A2 (de) 2014-04-30
WO2013003346A3 (en) 2013-02-28
CA2841158A1 (en) 2013-01-03
JP2014521600A (ja) 2014-08-28
RU2014102217A (ru) 2015-08-10
AU2012275552A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
HK1201152A1 (en) Dermal delivery compositions and methods
HK1199694A1 (zh) 益生菌組合物和方法
IL230237B (en) Fat Cell Compounds and Methods
EP2536293A4 (de) Verfahren und zusammensetzungen zur verwendung in einer aquakultur
EP2665726A4 (de) Zusammensetzungen und verfahren zur behandlung kardiovaskulärer erkrankungen
HK1204892A1 (en) Improvements in and relating to cushions
EP2680837A4 (de) Zusammensetzungen und verfahren mit c16:1n7-palmitoleat
HK1220912A1 (zh) 減少身體脂肪的方法和成份
ZA201307187B (en) Synergistic compositions and methods
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP2629742A4 (de) Haarpflegezusammensetzungen und zugehörige verfahren
HK1199378A1 (en) Compositions and methods for use in promoting lean body mass
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
EP2785823A4 (de) Reinigungszusammensetzungen und verfahren
EP2739318A4 (de) Inline-sterilisator
GB201117106D0 (en) Prosthesis and methods and uses involving said prosthesis
ZA201308892B (en) Compositions and methods
EP2678339A4 (de) Verfahren und zusammensetzungen zur behandlung von beta-thalassämie und sichelzellanämie
EP2668044A4 (de) Zusammensetzungen und ihre verwendung
ZA201305342B (en) Improvements in and relating to compositions
EP2766357A4 (de) Mesobiliverdinzusammensetzungen und verfahren dafür
IL227384A0 (en) Metal steaming compounds and methods for chemical-mechanical polishing
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
EP2723349A4 (de) Mikro-rna-31-zusammensetzungen und verfahren zu ihrer verwendung bei autoimmunkrankheiten
GB201113581D0 (en) Throw in platform

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7088 20060101AFI20141128BHEP

Ipc: C12N 15/113 20100101ALI20141128BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20141212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150723